Pedaling away chemo pain: new study tests cycling as a remedy for nerve damage
NCT ID NCT07150117
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a 12-week supervised cycling program can reduce nerve pain and improve quality of life in 30 adults who have had chemotherapy for cancer. Participants will ride a stationary bike twice a week for up to an hour. The main goal is to see if people find the program acceptable and if a larger trial is worth doing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- supervised stationary cycling exercise program
- What this could lead to
- If it works, this could point toward a simple, drug-free way to reduce nerve pain and improve daily function for cancer survivors.
- What could go wrong
- This is a very small, early proof-of-concept study with only 30 people. It is designed to see if a larger trial is even possible, not to prove the exercise works. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years or older * Cancer diagnosis stage I to III * CIPN: grade 1 (mild) * Receiving or have received chemotherapy treatment for cancer * Speak, read and understand English Exclusion Criteria: * Medical conditions that cause additional neuropathy symptoms (i.e. diabetes) * Any uncontrolled medical conditions * Will undergo surgery or radiation therapy during the study period * Are already receiving an aerobic exercise training program * Are already participating in an exercise-based research study * Are unable to provide signed informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adults are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Can a broader rehab programme help people with low vision live better?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success